Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2014

01-02-2014 | Research Article

PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer

Authors: J. Li, Z. Yang, Q. Zou, Y. Yuan, J. Li, L. Liang, G. Zeng, S. Chen

Published in: Clinical and Translational Oncology | Issue 2/2014

Login to get access

Abstract

Purpose

To identify biological markers related to the progression and prognosis of GBC.

Methods

The expressions of pyruvate kinase isoenzyme type M2 (PKM2) and activin A receptor type IC (ACVR 1C) in 46 squamous cell/adenosquamous carcinomas (SC/ASC) and 80 adenocarcinomas (AC) were examined using immunohistochemistry.

Results

Positive PKM2 and negative ACVR 1C expressions were significantly associated with lymph node metastasis, invasion and TNM stage of SC/ASCs and ACs. Univariate Kaplan–Meier analysis showed that either elevated PKM2 or loss of ACVR 1C expression significantly correlated with shorter average survival times in both SC/ASC and AC patients. Multivariate Cox regression analysis showed that positive PKM2 expression and loss of ACVR 1C expression were poor prognosis biomarkers in both SC/ASC and AC patients.

Conclusions

Our study suggested that PKM2 overexpression is a marker of metastasis, invasion and poor prognosis of GBC. ACVR 1C is a tumor suppressor, and lowered ACVR 1C expression is an important marker for the metastasis, invasion, and prognosis of GBC.
Literature
1.
Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:331–42.PubMedCrossRef
2.
Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5.PubMedCrossRef
3.
de Aretxabala X, Roa I, Burgos L, Losada H, Roa JC, Mora J, et al. Gallbladder cancer: an analysis of a series of 139 patients with restricted to the subserosal layer. J Gastrointest Surg. 2006;10:186–92.PubMedCrossRef
4.
Ootani T, Shirai Y, Tsukada K, Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992;69:2647–52.PubMedCrossRef
5.
Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, et al. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol. 2011;24:1069–78.PubMedCrossRef
6.
Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2011;43:969–80.PubMedCrossRef
7.
Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15:300–8.PubMedCrossRef
8.
Spoden GA, Mazurek S, Morandell D, Bacher N, Ausserlechner MJ, Jansen-Dürr P, et al. Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer. 2008;123:312–21.PubMedCrossRef
9.
Jiang K, He B, Lai L, Chen Q, Liu Y, Guo Q, et al. Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2. Int J Mol Med. 2012;30:302–8.PubMed
10.
11.
Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J. 2008;55:11–21.PubMedCrossRef
12.
Angenete E, Langenskiöld M, Palmgren I, Falk P, Oresland T, Ivarsson ML. Transforming growth factor beta-1 in rectal tumor, mucosa and plasma in relation to radiotherapy and clinical outcome in rectal cancer patients. Int J Colorectal Dis. 2007;22:1331–8.PubMedCrossRef
13.
Joshi A, Cao D. TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. Front Biosci. 2010;15:180–94.CrossRef
14.
Liu DC, Yang ZL, Jiang S. Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol Oncol Res. 2011;17:859–66.PubMedCrossRef
15.
Kondo M, Dono K, Sakon M, Shimizu J, Nagano H, Nakamori S, et al. Adenosquamous carcinoma of the gallbladder. Hepatogastroenterology. 2002;49:1230–4.PubMed
16.
Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc. 2007;4:99–124.PubMed
17.
Hoda MA, Münzker J, Ghanim B, Schelch K, Klikovits T, Laszlo V, et al. Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. Br J Cancer. 2012;107:1978–86.PubMedCentralPubMedCrossRef
Metadata
Title
PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer
Authors
J. Li
Z. Yang
Q. Zou
Y. Yuan
J. Li
L. Liang
G. Zeng
S. Chen
Publication date
01-02-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1063-8

Other articles of this Issue 2/2014

Clinical and Translational Oncology 2/2014 Go to the issue

Research Article

Selecting housekeeping genes as references for the normalization of quantitative PCR data in breast cancer

Research Article

Proteomic analysis of pleural effusion from lung adenocarcinoma patients by shotgun strategy

Research Article

To evaluate the accuracy of dynamic versus static IMRT delivery using portal dosimetry

Erratum

Erratum to: PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer

Research Article

The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme

Research Article

The adiponectin gene single-nucleotide polymorphism rs1501299 is associated with hepatocellular carcinoma risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits